Key Segmentation
By Test Type
- Glucose Testing
- Complete Blood Count
- Lipid Profile Testing
- Infectious Disease Testing
- Coagulation Testing
- A1C Testing
- Kidney/Renal Function Testing
- Liver Function Testing
- Cancer/Oncology Testing
- Others
By Product
- Reagents and Kits
- Instruments
- Software and Services
By Method
- Automated
- Manual
By End Use
- Hospitals and Clinics
- Diagnostic Laboratories
- Home Care Settings
- Blood Banks
- Research Institutions/Laboratories
- Others
Regional Coverage:
North America
- US
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- ASEAN Countries
- Rest of Asia Pacific
Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of Middle East & Africa
Latin America
- Brazil
- Argentina
- Mexico
- Colombia
- Rest of Latin America
Available Customization
With the given market data SNS Insider offers customization as per the company's specific needs. The following customization options are available for the report:
- Detailed Volume Analysis
- Criss-Cross segment analysis (e.g. Type X Application)
- Competitive Product Benchmarking
- Geographic Analysis
- Additional countries in any of the regions
- Customized Data Representation
- Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Danaher Corporation, and Becton, Dickinson and Company, among other diagnostics manufacturers.
Continued development of novel blood-based biomarker tests and continued expansion of point-of-care blood testing represent the primary opportunities.
Growth is primarily driven by the growing burden of chronic and infectious diseases, combined with continued laboratory automation.
By Test Type, Glucose Testing dominated the market in 2025, reflecting the enormous and still-growing global diabetic patient population.
North America dominated the market with a 34.65% share in 2025, supported by a vast clinical laboratory infrastructure and broad insurance coverage.
